We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.
- Authors
Bissonnette, R.; Saint‐Cyr Proulx, E.; Jack, C.; Maari, C.
- Abstract
Tapinarof is a topical, aryl‐hydrocarbon receptor agonist that has recently received FDA‐approval for the treatment of psoriasis. This novel therapeutic has also been shown to be effective for atopic dermatitis and is currently in phase 3 for this indication. Beyond good efficacy and fast onset of action in patients with psoriasis, the clinical response to tapinarof is notable for durable remission or near remission, maintained for an average of 130 days beyond treatment discontinuation in patients with psoriasis in phase 3 studies. Tapinarof is usually well tolerated but can induce a follicular inflammatory reaction and dermatitis in some patients. This narrative review covers the historical development of this molecule, safety and efficacy data from clinical trials conducted with various topical formulations, and practical considerations derived from our 15 years of clinical trial experience with the drug.
- Subjects
UNITED States. Food &; Drug Administration; ATOPIC dermatitis; MEDICAL research; PSORIASIS; TERMINATION of treatment; CLINICAL trials
- Publication
Journal of the European Academy of Dermatology & Venereology, 2023, Vol 37, Issue 6, p1168
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.18925